Rise in HMPV cases in China raises alarm over seasonal respiratory risks

The surge in human metapneumovirus (HMPV) cases recently reported in China has drawn the attention of health authorities and experts worldwide. First identified in 2001, HMPV is a respiratory virus belonging to the Pneumoviridae family, known to cause both upper and lower respiratory tract infections. Hospitals in China have reported a significant increase in pediatric and elderly hospitalizations due to complications related to the virus. While most cases result in mild symptoms, vulnerable populations can experience severe outcomes, such as bronchiolitis and pneumonia.

Reports indicate that since November 2024, HMPV cases have been rising not only in China but also in the United States. According to CDC data, 1.94% of weekly tests conducted through December 28 tested positive for HMPV, compared to 18.71% for influenza and 7.10% for COVID-19. International authorities are closely monitoring the situation, while the Chinese Center for Disease Control and Prevention (CCDC) steps up measures to contain respiratory infections during the winter.

Unlike the early days of the COVID-19 pandemic, experts affirm that HMPV does not pose a similar threat. However, its high transmissibility and the absence of a vaccine make preventive measures and monitoring crucial during periods of increased respiratory virus circulation.

What is HMPV, and how was it discovered?

Human metapneumovirus was identified just over two decades ago and is now recognized as a leading cause of respiratory infections in children and the elderly. Despite its relatively recent discovery, researchers believe the virus had been circulating long before its official identification in 2001. Studies suggest that nearly all children are exposed to HMPV by the age of five, gaining partial immunity.

Technological advances in recent decades have allowed for more precise and rapid diagnostics. Respiratory panels now commonly available in hospitals and laboratories can identify HMPV, distinguishing it from other viruses like influenza, RSV, and COVID-19. This has led to a deeper understanding of its prevalence and public health impact.

Primary symptoms and at-risk groups

HMPV symptoms range from mild to severe and are often mistaken for those of other respiratory infections. Common symptoms include cough, nasal congestion, fever, and shortness of breath. Severe cases, particularly in young children, the elderly, and immunocompromised individuals, may progress to bronchiolitis or pneumonia.

Experts have identified the following high-risk groups:

• Children under the age of five;
• Adults over the age of 65;
• Individuals with chronic conditions such as diabetes and heart disease;
• Immunocompromised individuals, including cancer patients.

While reinfection is possible, it typically manifests in milder forms among healthy individuals but can pose significant risks to vulnerable populations.

How is HMPV transmitted?

The transmission of human metapneumovirus occurs similarly to other respiratory viruses, such as influenza and RSV. Key modes of transmission include:

1. Droplets expelled through coughing and sneezing;
2. Close personal contact with infected individuals;
3. Touching contaminated surfaces and then contacting the eyes, nose, or mouth.

Studies indicate that the virus can survive on surfaces for several hours, emphasizing the importance of regular hand hygiene and mask use in high-risk environments.

Current situation and impact in China

The surge in HMPV cases in China comes amid increased circulation of respiratory viruses during the winter months. Reports from northern provinces reveal that pediatric hospitals are experiencing high demand, with long wait times and healthcare staff under strain. However, Chinese authorities assure that the situation is under control, with total respiratory infection numbers lower than those recorded during the same period last year.

The increase coincides with higher population mobility during the year-end holiday season and the Lunar New Year, events that involve large gatherings and extensive domestic travel. These factors create an environment conducive to the spread of respiratory illnesses.

Comparison with other respiratory viruses

HMPV shares characteristics with other known respiratory viruses but has distinct features. Unlike SARS-CoV-2, which causes COVID-19, metapneumovirus is not associated with significant mutations or global pandemic potential. Nevertheless, its seasonal presence in various regions requires constant vigilance from health authorities.

In the United States, HMPV represents a smaller proportion of respiratory infections compared to influenza and RSV. However, its detection in 1.94% of tests conducted during late December 2024 highlights its relevance in the broader context of seasonal respiratory illnesses.

Prevention and disease management

With no specific vaccines or antivirals available for HMPV, prevention relies entirely on basic hygiene practices and responsible behaviors. Key recommendations include:

• Washing hands frequently with soap and water for at least 20 seconds;
• Wearing masks in indoor and crowded spaces;
• Covering the mouth and nose when coughing or sneezing;
• Avoiding close contact with sick individuals;
• Regularly disinfecting commonly touched surfaces.

Clinical management of HMPV focuses on supportive care, such as using bronchodilators to ease breathing in cases of wheezing and administering fluids to prevent dehydration. Antibiotics may be necessary in cases of secondary bacterial infections.

Interesting facts about HMPV

1. Studies show that HMPV accounts for approximately 5% to 10% of hospitalizations due to respiratory infections in children.
2. Although less well-known than other respiratory viruses, it is frequently identified in localized outbreaks in daycare centers and schools.
3. HMPV circulation follows a seasonal pattern, with peak activity during winter months, similar to influenza and RSV.

Global impacts and epidemiological surveillance

Although the current HMPV outbreak is concentrated in China, the global community remains on high alert. Countries with direct flights from affected regions have intensified health screenings, while experts continue monitoring data to evaluate potential global implications.

Organizations like the WHO emphasize that despite the rise in cases, there is no evidence suggesting HMPV poses a significant public health threat worldwide. However, the outbreak underscores the importance of maintaining robust epidemiological surveillance and emergency health response capabilities.

Importance of vaccines against other viruses

While no specific vaccine exists for HMPV, immunization against influenza, COVID-19, and RSV plays a crucial role in reducing the overall impact of respiratory infections. These vaccines not only protect against severe diseases but also lower the risk of co-infections, which can lead to more severe outcomes.